NCT02530476 2020-03-31
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
Clinical Trials
6 trialsNCT02196857 2020-01-14
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00542971 2018-08-23
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00943943 2017-03-29
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01254890 2016-05-06
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00665990 2015-01-09
Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
St. Jude Children's Research Hospital
Phase 1 Completed